ERBB2 and neoplasm: Recurrences developed in 16 of these 334 women: four women with triple-negative tumours, all of whom developed locoregional recurrences after completing chemotherapy, one woman with HR-positive/HER2-positive diseases, who developed locoregional recurrences after chemotherapy/trastuzumab, and 11 women with ER-positive/HER2-negative tumours, six of whom had received chemotherapy and developed three locoregional and three systemic recurrences and five of whom had declined to undergo chemotherapy and developed two locoregional and three systemic recurrences.